Your browser doesn't support javascript.
loading
Identification of biomarkers predictive of metastasis development in early-stage colorectal cancer using network-based regularization.
Peixoto, Carolina; Lopes, Marta B; Martins, Marta; Casimiro, Sandra; Sobral, Daniel; Grosso, Ana Rita; Abreu, Catarina; Macedo, Daniela; Costa, Ana Lúcia; Pais, Helena; Alvim, Cecília; Mansinho, André; Filipe, Pedro; Costa, Pedro Marques da; Fernandes, Afonso; Borralho, Paula; Ferreira, Cristina; Malaquias, João; Quintela, António; Kaplan, Shannon; Golkaram, Mahdi; Salmans, Michael; Khan, Nafeesa; Vijayaraghavan, Raakhee; Zhang, Shile; Pawlowski, Traci; Godsey, Jim; So, Alex; Liu, Li; Costa, Luís; Vinga, Susana.
Afiliación
  • Peixoto C; INESC-ID, Instituto Superior Técnico, Universidade de Lisboa, Rua Alves Redol 9, 1000-029, Lisbon, Portugal.
  • Lopes MB; NOVA Laboratory for Computer Science and Informatics (NOVA LINCS), NOVA School of Science and Technology, 2829-516, Caparica, Portugal.
  • Martins M; Center for Mathematics and Applications (NOVA MATH), NOVA School of Science and Technology (FCT NOVA), 2829-516, Caparica, Portugal.
  • Casimiro S; Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
  • Sobral D; Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
  • Grosso AR; Associate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.
  • Abreu C; UCIBIO - Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.
  • Macedo D; Associate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.
  • Costa AL; UCIBIO - Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.
  • Pais H; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Alvim C; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Mansinho A; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Filipe P; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Costa PMD; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Fernandes A; Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
  • Borralho P; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Ferreira C; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Malaquias J; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Quintela A; Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
  • Kaplan S; Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
  • Golkaram M; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Salmans M; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Khan N; Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
  • Vijayaraghavan R; Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
  • Zhang S; Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
  • Pawlowski T; Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
  • Godsey J; Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
  • So A; Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
  • Liu L; Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
  • Costa L; Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
  • Vinga S; Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
BMC Bioinformatics ; 24(1): 17, 2023 Jan 16.
Article en En | MEDLINE | ID: mdl-36647008
ABSTRACT
Colorectal cancer (CRC) is the third most common cancer and the second most deathly worldwide. It is a very heterogeneous disease that can develop via distinct pathways where metastasis is the primary cause of death. Therefore, it is crucial to understand the molecular mechanisms underlying metastasis. RNA-sequencing is an essential tool used for studying the transcriptional landscape. However, the high-dimensionality of gene expression data makes selecting novel metastatic biomarkers problematic. To distinguish early-stage CRC patients at risk of developing metastasis from those that are not, three types of binary classification approaches were used (1) classification methods (decision trees, linear and radial kernel support vector machines, logistic regression, and random forest) using differentially expressed genes (DEGs) as input features; (2) regularized logistic regression based on the Elastic Net penalty and the proposed iTwiner-a network-based regularizer accounting for gene correlation information; and (3) classification methods based on the genes pre-selected using regularized logistic regression. Classifiers using the DEGs as features showed similar results, with random forest showing the highest accuracy. Using regularized logistic regression on the full dataset yielded no improvement in the methods' accuracy. Further classification using the pre-selected genes found by different penalty factors, instead of the DEGs, significantly improved the accuracy of the binary classifiers. Moreover, the use of network-based correlation information (iTwiner) for gene selection produced the best classification results and the identification of more stable and robust gene sets. Some are known to be tumor suppressor genes (OPCML-IT2), to be related to resistance to cancer therapies (RAC1P3), or to be involved in several cancer processes such as genome stability (XRCC6P2), tumor growth and metastasis (MIR602) and regulation of gene transcription (NME2P2). We show that the classification of CRC patients based on pre-selected features by regularized logistic regression is a valuable alternative to using DEGs, significantly increasing the models' predictive performance. Moreover, the use of correlation-based penalization for biomarker selection stands as a promising strategy for predicting patients' groups based on RNA-seq data.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Colorrectales Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Bioinformatics Asunto de la revista: INFORMATICA MEDICA Año: 2023 Tipo del documento: Article País de afiliación: Portugal

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Colorrectales Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Bioinformatics Asunto de la revista: INFORMATICA MEDICA Año: 2023 Tipo del documento: Article País de afiliación: Portugal